Find link

language:

Find link is a tool written by Edward Betts.

searching for Sipuleucel-T 9 found (24 total)

Dendreon (1,588 words) [view diff] exact match in snippet view article find links to article

biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer. It consists of a mixture of

Therapeutic vaccines (1,116 words) [view diff] exact match in snippet view article find links to article

approved by USA Food and Drug Administration, as following; Provenge is Sipuleucel-T, a dendritic cell based vaccine for prostate cancer. Bacillus Calmettle-Guerin

Kevin Kimberlin (1,011 words) [view diff] exact match in snippet view article find links to article

pp. 432. ISBN 9780199334414. immune response corporation kimberlin. "Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine". Drugs in R&D. 7 (3): 197–201

Leukapheresis (637 words) [view diff] exact match in snippet view article find links to article

O, Salama A. Kantoff P.W., Higano C.S., Shore N.D.; et al. (2010). "Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer". N Engl J Med

Michael Palese (2,336 words) [view diff] exact match in snippet view article find links to article

Evaluate Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen (P07-2). GCO 09–1509. An open label study of sipuleucel-T in men with

Neuvenge (1,114 words) [view diff] exact match in snippet view article find links to article

Responses for the 2010 PLI at Dendreon's Manufacturing Facility for Sipuleucel-T at Morris Plains, New Jersey - Provenge". U.S. Food and Drug Administration

Cancer prevention (4,232 words) [view diff] exact match in snippet view article find links to article

released or are undergoing clinical trial. FDA-approved vaccines, such as Sipuleucel-T for metastasizing prostate cancer or Nivolumab for melanoma and lung

Flutamide (10,977 words) [view diff] exact match in snippet view article find links to article

PMC 10355925. PMID 26024831. S2CID 10625154. Slovin SF (29 September 2015). "Sipuleucel-T - A Model for Immunotherapy Trial Development". In Mydlo JH, Godec CJ

Nicholas J. Vogelzang (2,616 words) [view diff] exact match in snippet view article find links to article

in April 2009 and is supported by Cougar Biotechnology. A Registry of Sipuleucel-T Therapy in men with advanced prostate Cancer. The study began in June